Phenominer Database Results (30 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 472.0 % 127.0 439.94 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection 70% hepatectomy group POD 17 110998 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2.32 cm3 0.59 2.04 magnetic resonance imaging liver 0.0 31 days 30% hepatectomy group POD24 30% hepatectomy group POD24 110987 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 3.2 cm3 0.62 2.15 magnetic resonance imaging liver 0.0 31 days portal vein occlusion group POD24 portal vein occlusion group POD24 110989 3191
BDIX/OrlCrl calculated liver volume DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 3.73 cm3 0.21 0.73 magnetic resonance imaging liver 0.0 5 days portal vein occlusion group baseline portal vein occlusion group baseline 110812 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2039.0 % 562.0 1946.83 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection 30% hepatectomy group POD24 111004 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.67 cm3 0.13 0.45 magnetic resonance imaging liver 0.0 24 days sham surgical group POD17 sham surgical group POD17 110823 3191
BDIX/OrlCrl calculated liver volume DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 3.62 cm3 0.29 1.0 magnetic resonance imaging liver 0.0 5 days 70% hepatectomy group baseline 70% hepatectomy group baseline 110811 3191
BDIX/OrlCrl liver volume after excision and regeneration DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 10 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 8.1 cm3 1.07 3.71 magnetic resonance imaging liver 0.0 10 days 10 days after tumor cell injection portal vein occlusion group POD10 110814 3191
BDIX/OrlCrl post excision/regeneration liver volume to original liver volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 10 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 237.0 % 19.6 67.9 magnetic resonance imaging liver 0.0 10 days 10 days after tumor cell injection 70% hepatectomy group POD 10 110815 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.79 cm3 0.15 0.52 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection portal vein occlusion group POD17 110993 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2.3 cm3 0.74 2.56 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection sham surgical group POD24 110996 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 548.0 % 118.0 408.76 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection 30% hepatectomy group POD17 110999 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 518.0 % 117.0 405.3 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection sham surgical group POD17 111000 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2112.0 % 618.0 2140.81 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection sham surgical group POD24 111001 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 725.0 % 151.0 523.08 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection portal vein occlusion group POD17 111002 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 1516.0 % 377.0 1305.97 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection 70% hepatectomy group POD 24 111003 3191
BDIX/OrlCrl subsequent liver tumorous lesion volume to precedent liver tumorous lesion volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2839.0 % 502.0 1738.98 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection portal vein occlusion group POD24 111005 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.9 cm3 0.16 0.55 magnetic resonance imaging liver 0.0 24 days portal vein occlusion group POD17 portal vein occlusion group POD17 110824 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.7 cm3 0.12 0.42 magnetic resonance imaging liver 0.0 24 days 30% hepatectomy group POD17 30% hepatectomy group POD17 110822 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.52 cm3 0.14 0.48 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection 70% hepatectomy group POD 17 110990 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.56 cm3 0.13 0.45 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection sham surgical group POD17 110992 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 1.67 cm3 0.38 1.32 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection 70% hepatectomy group POD 24 110994 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2.21 cm3 0.58 2.01 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection 30% hepatectomy group POD24 110995 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.63 cm3 0.14 0.48 magnetic resonance imaging liver 0.0 24 days 70% hepatectomy group POD17 70% hepatectomy group POD 17 110821 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then sham surgical control condition (0 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 2.41 cm3 0.74 2.56 magnetic resonance imaging liver 0.0 31 days sham surgical group POD24 sham surgical group POD24 110988 3191
BDIX/OrlCrl liver volume after excision and regeneration DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (for 10 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 8.7 cm3 0.83 2.88 magnetic resonance imaging liver 0.0 10 days 10 days after tumor cell injection 70% hepatectomy group POD 10 110813 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (30 %) (for 17 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 0.59 cm3 0.12 0.42 magnetic resonance imaging liver 0.0 0 17-24 days after tumor cell injection 30% hepatectomy group POD17 110991 3191
BDIX/OrlCrl increase in liver tumorous lesion volume between two points in time DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 3.09 cm3 0.62 2.15 magnetic resonance imaging liver 0.0 0 17-31 days after tumor cell injection portal vein occlusion group POD24 110997 3191
BDIX/OrlCrl calculated liver tumorous lesion volume measurement DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then partial hepatectomy (70 %) (between 17 and 31 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver integrity trait male 0 days 12 1.78 cm3 0.38 1.32 magnetic resonance imaging liver 0.0 31 days 70% hepatectomy group POD24 70% hepatectomy group POD 24 110986 3191
BDIX/OrlCrl post excision/regeneration liver volume to original liver volume ratio DHD/K12/TRb cells (1.5 x 10E6 cells) (for 7 days) and DHD/K12/TRb cells (1 x 10E6 cells) (for 7 days) then hepatic portal vein occlusion (for 10 days) Schwarz L, etal., HPB (Oxford). 2020 Oct;22(10):1480-1489. doi: 10.1016/j.hpb.2020.02.008. Epub 2020 Mar 7. liver size trait male 0 days 12 220.0 % 25.3 87.64 magnetic resonance imaging liver 0.0 10 days 10 days after tumor cell injection portal vein occlusion group POD10 110816 3191